- The Notice indicated that the Company is not in compliance with the periodic financial report filing requirement set forth in Nasdaq Listing Rule 5250(c)(1) as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the "Second Quarter 10-Q"), by the applicable due date.
- The delay in filing the Second Quarter 10-Q is a result of the Company's need to restate certain previously filed financial statements.
Reported Friday, Cellectar Biosciences Announces Plan To Restate Financials, Delays 10-Q Filing, And Receives Nasdaq Non-Compliance Notification
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.